Corporate / M&A

Competition

Financing and Investment Products

IP / IT

Homburger News

20230331_Clearchannel

On March 31, 2023, Clear Channel Outdoor Holdings, Inc. (NYSE: CCO), a global out-of-home advertising company, announced that it has completed the sale of its business in Switzerland to Goldbach Group AG, an affiliate of TX Group AG, for CHF 86.0 m.
Homburger advises Clear Channel Outdoor Holdings, Inc. with regard to all Swiss legal aspects of this transaction. The Homburger team is led by Daniel Hasler and comprises Andrea Grimm Widmer, Magda Aref, Thierry Burckhardt and Mike Lerchmüller (all Corporate / M&amp;A), Richard Stäuber, Allegra Arnold and Katharina Bratvogel (all Competition), Eduard De Zordi and Sarah Fasel (both Financing and Investment Products), Peter Müller (Tax), Gregor Bühler and Philippe Baumann (both IP / IT).

Homburger advises Clear Channel on the successful closing of the sale of its Swiss business to TX Group

Healthcare / Life Sciences

Noema Pharma

On March 7, 2023, Noema Pharma AG announced that it has successfully closed an oversubscribed Series B financing round, raising CHF 103 m (approx. USD 112 m) from new and existing investors. The round was co-led by the European healthcare focused investment firms Forbion and Jeito Capital. UPMC Enterprises and an additional new investor joined existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus to complete the round.
Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The proceeds of the Series B financing will be used to advance Noema Pharma&#8217;s clinical-stage assets.
Homburger AG advises Noema Pharma AG as transaction counsel in this Series B financing round. The Homburger team comprised Andreas Müller, Margrit Marti, Timo Hasler, Thierry Burckhardt, Pepe Hünerwadel and Carolina Rodriguez (all Corporate / M&amp;A; Healthcare / Life Sciences), Luca Dal Molin (IP / IT; Healthcare / Life Sciences) as well as Stefan Oesterhelt and Laetitia Fracheboud (Tax).

Homburger advises Noema Pharma AG on its USD 112 m Series B financing round

Bioversys

On January 5, 2023, BioVersys AG, a privately held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation, announced that the AMR Action Fund has joined existing investors of BioVersys, extending the total proceeds of the Series C round to CHF 32.6 m. BioVersys represents the first European-based investment of the AMR Action Fund.
Homburger advised BioVersys in this transaction. The Homburger team comprised Dieter Gericke and Thierry Burckhardt (both Corporate / M&amp;A).

Homburger advised BioVersys AG on the extension of its Series C fundraising round

Thierry
Burckhardt

Homburger advises Clear Channel on the successful closing of the sale of its Swiss business to TX Group

Homburger advises Noema Pharma AG on its USD 112 m Series B financing round

Homburger advised BioVersys AG on the extension of its Series C fundraising round

Join the Team

Thierry Burckhardt

Career

Languages

Bar Registration

Teams

ThierryBurckhardt

Homburger advises Clear Channel on the successful closing of the sale of its Swiss business to TX Group

Homburger advises Noema Pharma AG on its USD 112 m Series B financing round

Homburger advised BioVersys AG on the extension of its Series C fundraising round

Join the Team

Thierry Burckhardt

Career

Languages

Bar Registration

Teams

Thierry
Burckhardt